BioSpace News Archive

Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022.

Neuronetics, Inc. today announced its financial and operating results for the second quarter of 2022.

Avidity Biosciences, Inc. today announced that it has commenced enrolling patients from the Phase 1/2 MARINA™ study into a Phase 2 open-label extension study (MARINA-OLE™) of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).

In the worldwide effort to control monkeypox, a novel and fast typing method to trace monkeypox virus strains was developed by Dutch company Molecular Biology Systems (MBS) in collaboration with the department of Medical Microbiology & Infectious Disease Prevention of the Amsterdam UMC and researchers of the Danish Rigshospitalet.

Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today reported that study data presented at the Alzheimer’s Association International Conference® 2022 (AAIC®) in San Diego.

Nordson Corporation announced it will release third quarter fiscal year 2022 earnings on August 22, 2022 after the close of the market.

Mycovia Pharmaceuticals, Inc. has announced that it will present topline results from two studies evaluating VIVJOA™.

Calidi Biotherapeutics, Inc. is pleased to announce that City of Hope has received U.S. Food and Drug Administration (FDA) authorization to proceed with a phase 1 physician-sponsored clinical trial that will use Calidi’s licensed oncolytic virotherapy platform, NSC-CRAd-S-pk7.

Synthego, the genome engineering company, announced the launch of Engineered Cell Libraries, a novel offering that further enables access to CRISPR by providing arrayed CRISPR-edited cells for direct use in functional screening assays.

On August 2, 2022, Chime Biologics, a leading CDMO that enables its partners’ success in biologics, announced that it has received the commercial manufacturing license from the National Medical Products Administration, which represents Chime Biologics has achieved another remarkable milestone by having established sound quality operations on commercial scale.